Lysogene (LYS.PA) Stock Price
Lysogene Price
Revenue has compounded at 32.6% per year over the past 7 years to 3.73 M EUR. Lysogene's net margin stands at -366.4%, up from -907.5% several years earlier.
Lysogene stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Lysogene over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Lysogene stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Lysogene's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Lysogene Price |
|---|
Lysogene Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Lysogene Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB EUR |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM EUR |
| EBITM EUR |
| EBIT MARGIN% |
| NET INCOMEM EUR |
| NET INCOME GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022e | 2023e | 2024e | 2025e | 2026e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | 0.01 | 0.01 | – | – | – | – | 0.46 | 1.15 |
| – | – | – | – | – | 333.33 | – | -76.92 | 33.33 | – | -25.00 | 15,233.33 | 150.00 |
| – | – | – | – | 100.00 | 76.92 | 76.92 | 33.33 | 33.33 | 33.33 | 33.33 | 33.33 | 33.33 |
| 1.00 | 1.00 | 1.00 | 2.00 | 3.00 | 10.00 | 10.00 | 1.00 | 1.33 | 1.33 | 1.00 | 153.33 | 383.33 |
| – | -3.00 | -7.00 | -17.00 | -10.00 | -5.00 | -5.00 | -13.00 | -18.00 | -22.00 | -24.00 | 350.00 | 875.00 |
| – | – | – | – | -333.33 | -38.46 | -38.46 | -433.33 | -450.00 | -550.00 | -800.00 | 76.09 | 76.09 |
| – | -3.00 | -7.00 | -17.00 | -10.00 | -3.00 | -5.00 | -13.00 | – | – | -21.00 | 258.00 | 646.00 |
| – | – | 133.33 | 142.86 | -41.18 | -70.00 | 66.67 | 160.00 | – | – | – | -1,328.57 | 150.39 |
| 8.25 | 8.25 | 11.71 | 12.58 | 13.59 | 13.62 | 16.79 | 17.19 | 17.19 | 17.19 | 17.19 | 17.19 | 17.19 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Lysogene generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Lysogene retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Lysogene's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Lysogene has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Lysogene's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Lysogene stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Lysogene Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Lysogene business model & stock analysis
Lysogene SWOT Analysis
Strengths
Lysogene SA has several key strengths that contribute to its success:
- Strong research and development capabilities.
- Solid intellectual property portfolio.
- Strong financial position and steady revenue growth.
- Well-established partnerships with leading pharmaceutical companies.
- Experienced and knowledgeable management team.
Weaknesses
Despite its strengths, Lysogene SA also faces certain weaknesses:
- Relatively small market presence compared to competitors.
- Limited product portfolio, reliant on a few key products.
- Lack of geographical diversification, with a focus on specific markets.
- Potential vulnerability to changes in regulatory environment.
- Challenges in attracting and retaining top talent in the highly competitive industry.
Opportunities
Lysogene SA can capitalize on the following opportunities:
- Expanding into new markets and geographies.
- Developing additional innovative products and treatment options.
- Leveraging advancements in technology for research and development.
- Increasing demand for gene therapy solutions.
- Strategic collaborations and partnerships with academic institutions.
Threats
Lysogene SA should be mindful of the following threats:
- Intense competition from existing and emerging players in the market.
- Stringent regulations and potential delays in obtaining necessary approvals.
- Rapidly changing technological landscape, requiring continuous adaptation.
- Economic and political uncertainties impacting the healthcare industry.
- Potential risks associated with clinical trials and adverse events.
Lysogene Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Lysogene historical P/E ratio, EBIT multiple, and P/S ratio
Lysogene annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Lysogene shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Lysogene shareholder structure
| % | Name |
|---|---|
21.05203% | |
5.63362% | |
4.95428% | |
4.19614% | |
2.40622% | |
2.32275% |
Lysogene Beneficial Ownership Filings (SEC 13D/G)
Lysogene Executives and Management Board
13 members · avg. age 55 · 38 % women
Ms. Karen Aiach (50)
Chairman of the Board, Chief Executive Officer, Founder · since 2019
457,219.00 EUR
Management
Mr. Stephane Des Aulnois
Chief Financial Officer
Dr. Mark Plavsic
Chief Technical Officer
Mr. Ralph Laufer
Chief Scientific Officer
Dr. Marie Deneux
Chief Regulatory Officer
Mr. Michael Hocquemiller
Head of Non-Clinical Development · since 2020
Dr. Sophie Olivier
Chief Medical Officer
Board of Directors
Mr. David Schilansky (46)
Independent Director · since 2017
Dr. Peter Lichtlen (52)
Independent Director · since 2018
Mr. Philippe Goupit (66)
Independent Director
Dr. Mathieu Simon (65)
Independent Director
Ms. Carole Deffez (52)
Independent Director
Frequently asked questions about Lysogene
Lysogene SA operates as a biopharmaceutical company focused on the development of gene therapy treatments for rare central nervous system disorders. The company primarily targets diseases such as Sanfilippo syndrome, mucopolysaccharidosis type IIIA. Lysogene's business model revolves around the research, development, and potential commercialization of its proprietary gene therapy platform. By leveraging its expertise in gene therapy, Lysogene aims to provide transformative treatments for patients suffering from debilitating genetic disorders. Through strategic partnerships, collaborations, and clinical trials, Lysogene seeks to bring significant advancements in addressing unmet medical needs and improving the quality of life for affected individuals.
Lysogene SA is primarily active in the biotechnology industry.
The main competitors of Lysogene SA in the market are companies such as Sangamo Therapeutics, Abeona Therapeutics, and Orchard Therapeutics.
Lysogene SA is a renowned biotechnology company with a rich history and background. Founded in 2009, the company is based in France and focuses on developing innovative gene therapy treatments for severe genetic disorders affecting the central nervous system. Lysogene SA has dedicated its efforts to transforming patients' lives by designing therapies based on viral vectors to target specific proteins responsible for neurodegenerative diseases. Through extensive research and collaboration with experts, the company aims to provide effective and safe treatments for patients worldwide. With a strong commitment to advancing gene therapies, Lysogene SA continues to pioneer breakthroughs in the field of rare genetic disorders.
Lysogene SA has achieved several significant milestones in its history. Some notable achievements include the successful completion of Phase 2/3 clinical trials for its leading therapeutic candidate, LYS-SAF302. The company also received Orphan Drug Designations from both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of Sanfilippo Syndrome Type A. Furthermore, Lysogene SA has established global partnerships and collaborations to advance research and development efforts. These achievements showcase Lysogene SA's commitment to developing innovative therapies for rare genetic diseases, making it a promising player in the biopharmaceutical industry.
Lysogene SA is primarily present in France and the United States.
Lysogene SA represents values of innovation, commitment, and integrity. This biopharmaceutical company specializes in developing gene therapies for central nervous system disorders. Lysogene's corporate philosophy is centered around advancing scientific research to provide effective treatments for rare genetic diseases. With a strong focus on patient care and well-being, Lysogene strives to improve the quality of life for individuals suffering from disorders such as MPS IIIA and GM1 gangliosidosis. Through their dedication to scientific advancements and ethical business practices, Lysogene SA aims to make a positive impact in the field of genetic therapies and bring hope to patients and their families.
7 analysts currently rate the Lysogene stock: 0 recommend buying, 3 holding and 4 selling.
The Lysogene share (LYS.PA) is listed on 5 stock exchanges, including: Frankfurt (4W4.F), München (4W4.MU), London (0RNL.L), Paris (LYS.PA).
Lysogene SA is a French biotechnology company specialized in the development of gene therapy products for the treatment of rare neurological diseases. The company was founded in 2009 and is based in Paris. Lysogene's business model is based on the development and commercialization of gene therapy products for rare diseases caused by faulty genes. Lysogene works closely with leading researchers and clinics to develop groundbreaking gene therapies that can improve the lives of patients with rare diseases. The company operates in two main areas: research and development, and the commercialization of gene therapy products. Research and development: Lysogene heavily invests in the research and development of gene therapy products for rare neurological diseases. The company works closely with universities and research institutions to develop and test new therapies. The company's main product currently is a gene therapy for the treatment of Sanfilippo Syndrome Type A, a rare disease caused by genetic defects that affects the nervous system. The product, marketed under the name LYS-SAF302, is currently in Phase 1/2 of clinical trials. Commercialization of gene therapy products: An important goal of Lysogene is to market its gene therapy products and help patients worldwide. To achieve this, Lysogene works closely with regulatory authorities such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) to ensure that its products meet all necessary guidelines and regulations. The company also utilizes the latest technologies and distribution channels to successfully bring its gene therapy products to market. Lysogene has an experienced team of sales and marketing professionals who work closely with doctors, clinics, and patients to ensure that its products are accessible to as many people as possible. Summary: Overall, Lysogene focuses on the development and commercialization of gene therapy products for the treatment of rare neurological diseases. The company heavily invests in research and development to develop groundbreaking therapies that can improve patients' lives. Additionally, the company utilizes innovative technologies and distribution channels to successfully bring its products to market and support patients worldwide.
The revenue cannot currently be calculated for Lysogene.
The profit cannot currently be calculated for Lysogene.
The P/E ratio cannot be calculated for Lysogene at the moment.
The P/S cannot be calculated for Lysogene currently.
The Eulerpool Quality Score for Lysogene is 2/10.
The ISIN of Lysogene is FR0013233475. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Lysogene is A2DLMU. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Lysogene is LYS.PA. The ticker symbol is used to trade Lysogene shares on the stock exchange.
Lysogene is assigned to the 'Health' sector.
The dividends of Lysogene are distributed in EUR.
Lysogene stock
Lysogene Peer Group
Lysogene Ticker
Lysogene FIGI
All fundamentals and in-depth analysis of Lysogene
Our stock analysis for Lysogene stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lysogene. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.